吸入性变应原和口服糖皮质激素对过敏性哮喘患者血清可溶性CD86的影响

目的:探讨吸入变应原与口服糖皮质激素对过敏性哮喘患者血清可溶性CD86浓度的影响。方法:采用随机、双盲、安慰剂对照,平行分组,给予单相哮喘反应组和双相哮喘反应组患者吸入变应原,口服强的松或安慰剂,每天1次,共2周。吸入性变应原或强的松前后抽静脉血检验血清。用酶链免疫吸附分析法测定血清中sCD86浓度。结果:在吸入变应原后24 h,双相哮喘反应组血清sCD86浓度从(491.8±15.4)IU/ml上升到(603.8±19.3)IU/ml,而单相哮喘反应组sCD86浓度与基础值相比无显著提高。强的松治疗2周后血清sCD86与基础值相比显著下降,从(532.7±12.3)IU/ml下降至(448.3±15.1)IU/ml。而安慰剂组则没有显著下降。结论:该研究证实过敏性哮喘患者血清sCD86浓度在吸入变应原后升高,而用强的松治疗后其浓度则下降。

EFFECTS OF ALLERGEN INHALATION AND ORAL GLUCOCORTICOID ON SERUM SOLUBLE CD86 IN ALLERGIC ASTHMATICS

Objective:The aim of this study is to investigate effects of allergen inhalation and oral glucocorticoid on concentration of serum sCD86 in patients with allergic asthma.Methods:Allergen inhalation challenge was conducted in allergic asthmatics with isolated early asthma response and those with dual asthma response.In a randomized,double-blind,placebo-controlled,parallel group fashion,prednisolone or placebo was give orally once a day for 2 weeks.Venous blood samples were collected before and after allergen inhalation or prednisolone administration to obtaining sera.The serum sCD86 concentrations were determined by using enzyme-linked immunosorbent assay.Result:The serum soluble CD86 concentrations in the dual responder group increased from(491.8 F 15.4)IU/ml before allergen inhalation to(603.8 F 19.3)IU/ml 24 h after allergen inhalation.In the isolated early responders,there was no significant increase in serum soluble CD86 concentrations after allergen inhalation compared with baseline levels.There was a significant decrease in serum soluble CD86 concentrations after 2 weeks of glucocorticoid therapy(448.3 F 15.1 IU/ml) compared with baseline values(532.7 F 12.3 IU/ml),whereas there was no significant difference in the placebo group.Conclusion:This study has demonstrated that serum soluble CD86 concentrations increased after allergen inhalation in sensitized asthmatic subjects,and that serum sCD86 concentrations were down-regulated by prednisolone therapy.